NCT06822153View on ClinicalTrials.gov

Clinical Trial of the Effect of Methoxyethyl Etomidate Hydrochloride on the QT Interval of the Heart

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 9, 2023

Primary Completion Date

November 21, 2023

Study Completion Date

November 21, 2023

Conditions
QT Interval, Variation in
Interventions
DRUG

ET-26 0.8mg/kg(low-dose) group

In a 2:1 ratio, Placebo was administered with normal saline and ET-26 0.8mg/kg for a duration of 60 ±5 seconds.

DRUG

ET-26 2.8mg/kg(high dose) group

In a 2:1 ratio, Placebo was administered with normal saline and ET-26 2.8mg/kg for a duration of 60 ±5 seconds.

Trial Locations (1)

250013

Jinan Central Hospital, Jinan

Sponsors
All Listed Sponsors
lead

Ahon Pharmaceutical Co., Ltd.

OTHER